CapeOX (also called XELOX) is a combination of capecitabine and oxaliplatin.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Eloxatin (Sanofi-Aventis); Heloxatin
- INDICATIONS: Metastatic carcinoma of the colon or rectum (in combination with fluorouracil/leucovorin (FOLFOX; mFOLFOX6)). Advanced pancreatic cancer (in combination with irinotecan/fluorouracil/leucovorin (FOLFIRINOX or FOLFOXIRI)).
- CLASS: Alkylating agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Platinum-based antineoplastic
- HALF-LIFE: 391 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminoglycosides, BCG Vaccine, Capreomycin, Cardiac glycosides, Clozapine, Denosumab, Diuretics, Leflunomide, Natalizumab, Pimecrolimus, Polymyxins, Sipuleucel-T, Tacrolimus, Taxanes, Topotecan, Trastuzumab, Vaccines, Vitamin K antagonists
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
ANAPHYLACTIC REACTIONS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of oxaliplatin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/29/2025
